Development history and concept of an oral anticancer agent S-1 (TS-1®): Its clinical usefulness and future vistas

Japanese Journal of Clinical Oncology

Volumn 39, Issue 1, 2009, Pages 2-15

  Shirasaka, Tetsuhiko ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

5 FU (5 fluorouracil); Alternate day S 1 regimen; Balancing efficacy and toxicity; S 1 (TS 1 ); S 1 and low dose CDDP therapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; CAPECITABINE; CISPLATIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; OXONATE POTASSIUM; PACLITAXEL; TAXANE DERIVATIVE; TEGAFUR; TS 1; UFT; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BILIARY TRACT CANCER; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DERMATITIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HERPES ZOSTER; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PATIENT COMPLIANCE; PIGMENT DISORDER; REVIEW; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; FLUOROURACIL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS; OXONIC ACID; TEGAFUR;

EID: 58149383761     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn127     Document Type: Review

References (65)

1. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. J Am Med Assoc 1946;132:126-32. Reprinted in J Am Med Assoc 1984;251:2255-61.
2. Hata T, Sano R, Sugawara R, Matsumae A, Kanamori K, Shima T, et al. Mitomycin, a new antibiotic from Streptomyces. J Antib Ser A 1956;9:141-6.
3. Dushinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J Am Chem Soc 1957;79:4559-60.
4. MacDonald JS, Schein P, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93:533-6.
5. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.
6. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heiinicke A. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7:1310-7.
7. Wilkoff LJ, Wilcox WS, Burdeshaw JA, Dixon GJ, Dulmadge EA. Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. J Natl Cancer Inst 1967;39:965-75.
8. Skipper HE, Schabel FM, Jr, Melllet LB, Montgomery JA, Wilkoff LJ, Lloyd HH, et al. Implications of biochemical, cytokinetics, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54:431-50.
9. Shimoyama M, Kimura K. Quantitative study on cytocidal action of anticancer agents. Saisin Igaku 1973;28:1024-40 (in Japanese).
10. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal caner. J Clin Oncol 1998; 16:301-8.
11. 1-(a-furanidyl) derivative of natural pyrimidine bases and their antimetabolites. Dokl Akad Nauk SSSR 1967;176:332-5 (Chem Abstrt 1968;69:29664j).
12. Toide H, Akiyoshi H, Minato Y, Okuda H, Fujii S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann (Jpn J Cancer Res) 1977;68:553-60.
13. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000;6:4409-15.
14. Shimada T, Yamazaki H, Guengerich FP. Ethnic differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and caucasian population. Xenobiotica 1996;26:395-403.
15. Buroker T, Miller A, Baker L, McKenzie M, Somson M, Vaitkevicius VK. Phase II clinical trial of ftorafur in 5-fluorouracil refractory colorectal cancer. Cancer Treat Pep 1977;61:1579-80.
16. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouraciland level of 5-fluorouracil in rodents. Gann (Jpn J Cancer Res) 1979;70:209-14.
17. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rats liver extracts. Jpn J Cancer Res 1987;78:748-55.
18. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9.
19. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-cancer Drugs 1996;7:548-57.
20. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4 M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
21. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
22. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. S-1 Cooperative Study Group (Head and Neck Cancer Working Group) Late phase II study of S-1 in patients with advanced head and neck cancer. Jpn J Cancer Chemother 2001;28:1381-90.
23. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II Study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 2000; 83:141-5.
24. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004;100:2355-61.
25. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-4.
26. Hino M, Saeki T, Sano M. Late phase II of S-1 in patients with taxane resistant breast cancer. ASCO Annu Meeting 2004 (Abstract No 745).
27. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008;61:615-21.
28. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: A multicenter phase II study. Cancer Chemother Pharmacol 2008;62:849-55.
29. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fijii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20.
30. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-21.
31. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987;47:2203-6.
32. Houghton JA, Houghton PJ, Wooten RS. Mechanism of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 1979;39:2406-13.
33. Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 1984;44:1358-63.
34. Matsubara I, Kamiya J, Imai S. Cardiotoxic activity of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980;30:871-9.
35. Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970;23:155-60.
36. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008;14:8-13.
37. Shirasaka T, Shimamoto Y, Kato T, Fukushima M. Invention of tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil. Jpn J. Cancer Chemother 1998;25: 371-84.
38. Granat P, Creasey WA, Calabresi P, Handschumacher RE. Investigations with 5-azaorotic acid, an inhibitor of the biosynthesis of pyrimidine de novo. Clin Pharmacol Ther 1965;6:436-47.
39. Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T. Conceptual change in cancer chemotherapy: From an oral fluoropyrimidine drug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Investig New Drug 2000;18:315-29.
40. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic Study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-5.
41. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, et al. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 2002;20:1683-91.
42. Kim WY, Nakata B, Hirakawa K. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and α-fluoro-β-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci 2007;98:1604-8.
43. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-13.
44. Scanlon J, Newman EM, Lu Y. Biochemical basis for cisplatin and 5-fluolourasil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-5.
45. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumour models in vivo. Cancer Chemother Pharmacol 1993;32:167-72.
46. Araki H, Fukushima M, Kamiyama Y, Shirasaka T. Effect consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett 2000;160:185-91.
47. Kondo K, Murase M, Kodera Y, Akiyama S, Ito K, Yokoyama Y, et al. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 1996;53: 64-7.
48. Chung Y, Yamashita Y, Matsuoka T, Nakata T, Onoda N, Maeda K, et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997;80:1-7.
49. Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, et al. Combination phase I trail of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res 2004;10:1664-9.
50. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-21.
51. Hara T, Koizumi W, Narahara H, Takagane A, Akiya T, Takagi M, et al. Report of safety analysis in a randomized phase III study comparing S-1 alone with S-1 plus CDDP in advanced gastric cancer (The SPIRITS trial; TS-1 Advanced Gastric Cancer Clinical Trial Group). EJC 2007;5:264. #3516 (abstr).
52. Tsuji A, Shima Y, Morita S, Uchida M, Okamoto K, Morita M, et al. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: A retrospective study. Anticancer Res 2008;28:1433-8.
53. Lipkin M, Sherlock P, Bell B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterogy 1963;45:721-9.
54. Clarkson B, Ota K, Ohkita T, O'Connor A. Kinetics of proliferation of cancer cells in neoplastic effusions in man. Cancer 1965;18:1189-213.
55. Cronkite EP, Bond VP, Fliedner YM, Killmann SA. The use of tritiated thymidine in the study of haemopoietic cell proliferation. In: Wolsteinholme GEW, O'Connor M, editors. Ciba Foundation Symposium on Haemopoiesis. Boston: Little Brown & Co 1960;56, 70-98.
56. Saga Y, Suzuki M, Sato I, Shirasaka T. An in vitro examination of a 5-fluorouracil regimen involving continuous venous infusion using cultured cell lines derived from ovarian cancers. Oncol Rep 2000;7:625-8.
57. Arai W, Hosoya Y, Hyodo M, Haruta H, Kurashima K, Saito S, et al. Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell line in vitro and in vivo. Int Clin Oncol 2008;9 (in press).
58. Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y, Yasuda Y, et al. Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int Clin Oncol 2004;9:143-8.
59. Yamamitsu S, Kimura K, Yamada Y, Inui N, Hiyama S, Hirata K, et al. The first report from Sapporo Tsukisamu Hospital - Chemotherapy for patients with advanced pancreatic cancer. Jpn J Cancer Chemother 2007;34:1059-66.
60. Yamamitsu S, Kimura K, Yamada Y, Inui N, Hiyama S, Hirata K, et al. The second report from Sapporo Tsukisamu Hospital - Chemotherapy for patients with advanced colorectal cancer. Jpn J Cancer Chemother 2007;34:1241-7.
61. Yamamitsu S, Kimura K, Yamada Y, Inui N, Hiyama S, Hirata K, et al. The third report from Sapporo Tsukisamu Hospital - Chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa). Jpn J Cancer Chemother 2007;34:1241-7.
62. Yamamitsu S, Kimura K, Yamada Y, Inui N, Hiyama S, Hirata K, et al. The fourth report from Sapporo Tsukisamu Hospital - Chemotherapy and its regimen as second choice for patients with earky gastric cancer (peritoneal dissemination, peritonitis carcinomatosa). Jpn J Cancer Chemother 2007;34:1589-94.
63. Janu P, Li J, Renegar KB, Kudsk KA. Recovery of gut-associated lymphoid tissue and upper Respiratory tract immunity after parenteral nutrition. Ann Surg 1997;225:707-17.
64. King BK, Li J, Kudsk KA. A temporal study of TPN-induced changes in gut-associated lymphoid tissue and mucosal immunity. Arch Surg 1997;123:1303-9.
65. Yamashita T, Ueda Y, Fuji N, Itoh T, Kurioka H, Shirasaka T, et al. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol 2005;30:1-6.